This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with unresectable or metastatic colorectal cancer and other solid tumors failing standard therapies.

Trial Details

NCT ID
NCT07878988
Phase
PHASE1
Sponsor
LTZ Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • LTZ-232
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903

Key Eligibility Criteria

  • Advanced /metastatic colorectal tumors that have failed standard treatments
  • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
  • Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1
  • Adequate organ function based on laboratory testing

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →